RTH258A

Drug Novartis Pharma AG
Total Payments
$56,535
Transactions
135
Doctors
61
Companies
3

Payment Trends by Year

Year Amount Transactions Doctors
2018 $11,410 82 23
2017 $45,125 53 40

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $41,820 8 74.0%
Food and Beverage $6,919 81 12.2%
Travel and Lodging $5,276 45 9.3%
Unspecified $2,520 1 4.5%

Payments by Type

General
$54,015
134 transactions
Research
$2,520
1 transactions

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
OUTCOMES RESEARCH NOVARTIS PHARMACEUTICALS CORPORATION $2,520 1

Top Doctors Receiving Payments for RTH258A — Page 3

Doctor Specialty Location Total Records
, MD Ophthalmology Houston, TX $51.47 1
, MD Ophthalmology San Antonio, TX $51.47 1
, M.D Retina Specialist Colorado Springs, CO $51.47 1
, M.D Retina Specialist San Antonio, TX $51.47 1
, M.D Ophthalmology Arlington, TX $51.47 1
, M.D Retina Specialist St Petersburg, FL $51.47 1
, M.D Ophthalmology Austin, TX $51.47 1
, MD Ophthalmology Kingston, PA $51.47 1
, MD Ophthalmology Waldorf, MD $51.47 1
Jeffrey Heier Ophthalmology Boston, MA $14.00 1
, MD Ophthalmology Pasadena, CA $14.00 1

About RTH258A

RTH258A is a drug associated with $56,535 in payments to 61 healthcare providers, recorded across 135 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharma AG.

Payment data is available from 2017 to 2018. In 2018, $11,410 was paid across 82 transactions to 23 doctors.

The most common payment nature for RTH258A is "Consulting Fee" ($41,820, 74.0% of total).

RTH258A is associated with 1 research study, including "OUTCOMES RESEARCH" ($2,520).